Log In
BCIQ
Print this Print this
 

ExpressGraft Enhance skin substitute, ExpressGraft-C9T1

  Manage Alerts
Collapse Summary General Information
Company Mallinckrodt plc
DescriptionNontumorigenic, pathogen-free human keratinocyte progenitor cell line (NIKS) genetically modified to express hCAP-18, a human cathelicidin host defense peptide (HDP)
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationDermal ulcers
Indication DetailsTreat diabetic foot ulcers; Treat venous leg ulcers
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/31/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today